Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Jun;59(6):895–897. doi: 10.1038/bjc.1989.189

Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil.

S Merry 1, P Flanigan 1, E Schlick 1, R I Freshney 1, S B Kaye 1
PMCID: PMC2246748  PMID: 2736226

Full text

PDF
895

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benson A. B., 3rd, Trump D. L., Koeller J. M., Egorin M. I., Olman E. A., Witte R. S., Davis T. E., Tormey D. C. Phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat Rep. 1985 Jul-Aug;69(7-8):795–799. [PubMed] [Google Scholar]
  2. Carmichael J., DeGraff W. G., Gazdar A. F., Minna J. D., Mitchell J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987 Feb 15;47(4):936–942. [PubMed] [Google Scholar]
  3. Dowsett M., Harris A. L., Stuart-Harris R., Hill M., Cantwell B. M., Smith I. E., Jeffcoate S. L. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients. Br J Cancer. 1985 Oct;52(4):525–529. doi: 10.1038/bjc.1985.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hamann S. R., Todd G. D., McAllister R. G., Jr The pharmacology of verapamil. V. Tissue distribution of verapamil and norverapamil in rat and dog. Pharmacology. 1983;27(1):1–8. doi: 10.1159/000137823. [DOI] [PubMed] [Google Scholar]
  5. Kaye S., Merry S. Tumour cell resistance to anthracyclines--a review. Cancer Chemother Pharmacol. 1985;14(2):96–103. doi: 10.1007/BF00434344. [DOI] [PubMed] [Google Scholar]
  6. Merry S., Kaye S. B., Freshney R. I. Cross-resistance to cytotoxic drugs in human glioma cell lines in culture. Br J Cancer. 1984 Dec;50(6):831–835. doi: 10.1038/bjc.1984.263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Neugebauer G. Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog. Cardiovasc Res. 1978 Apr;12(4):247–254. doi: 10.1093/cvr/12.4.247. [DOI] [PubMed] [Google Scholar]
  8. Ozols R. F., Cunnion R. E., Klecker R. W., Jr, Hamilton T. C., Ostchega Y., Parrillo J. E., Young R. C. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol. 1987 Apr;5(4):641–647. doi: 10.1200/JCO.1987.5.4.641. [DOI] [PubMed] [Google Scholar]
  9. Slater L. M., Murray S. L., Wetzel M. W., Wisdom R. M., DuVall E. M. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J Clin Invest. 1982 Nov;70(5):1131–1134. doi: 10.1172/JCI110702. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES